Movement Alert｜HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications

Market Focus13:21

On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.

The rally was primarily driven by the simultaneous approval of two innovative drugs for new indications on August 6. Its subsidiary received NMPA approval for trastuzumab rezetecan injection for its third indication, targeting HER2-positive colorectal cancer patients who failed prior oxaliplatin, fluorouracil, and irinotecan treatment — making it the first anti-HER2 product approved for colorectal cancer in China. Meanwhile, the company's JAK1 inhibitor aimaxitinib tablets secured a fifth indication for active radiographic-negative axial spondyloarthritis, achieving full-spectrum oral targeted management coverage for axial spondyloarthritis.

Additionally, institutional interest has strengthened. Citigroup's long position in HENGRUI PHARMA H shares rose from 4.46% to 5.06% as of July 31, while Capital Group has been steadily accumulating shares. The board is scheduled to review interim results and consider a dividend on August 19.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185344761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185344761","market":"us","top_or_hot":-1,"title":"Movement Alert｜HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications","media":"Market Focus","content":"<p><p>On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.</p><p>The rally was primarily driven by the simultaneous approval of two innovative drugs for new indications on August 6. Its subsidiary received NMPA approval for trastuzumab rezetecan injection for its third indication, targeting HER2-positive colorectal cancer patients who failed prior oxaliplatin, fluorouracil, and irinotecan treatment — making it the first anti-HER2 product approved for colorectal cancer in China. Meanwhile, the company's JAK1 inhibitor aimaxitinib tablets secured a fifth indication for active radiographic-negative axial spondyloarthritis, achieving full-spectrum oral targeted management coverage for axial spondyloarthritis.</p><p>Additionally, institutional interest has strengthened. Citigroup's long position in HENGRUI PHARMA H shares rose from 4.46% to 5.06% as of July 31, while Capital Group has been steadily accumulating shares. The board is scheduled to review interim results and consider a dividend on August 19.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.</p><p>The rally was primarily driven by the simultaneous approval of two innovative drugs for new indications on August 6. Its subsidiary received NMPA approval for trastuzumab rezetecan injection for its third indication, targeting HER2-positive colorectal cancer patients who failed prior oxaliplatin, fluorouracil, and irinotecan treatment — making it the first anti-HER2 product approved for colorectal cancer in China. Meanwhile, the company's JAK1 inhibitor aimaxitinib tablets secured a fifth indication for active radiographic-negative axial spondyloarthritis, achieving full-spectrum oral targeted management coverage for axial spondyloarthritis.</p><p>Additionally, institutional interest has strengthened. Citigroup's long position in HENGRUI PHARMA H shares rose from 4.46% to 5.06% as of July 31, while Capital Group has been steadily accumulating shares. The board is scheduled to review interim results and consider a dividend on August 19.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1185344761","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185344761","pubTimestamp":1786080078,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.The rally was primarily driven by the simultaneous approval of two innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"异动提醒|恒瑞医药常规交易大涨3.1% 两款创新药获批新适应症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.The rally was primarily driven by the simultaneous approval of two innovative drugs for new indications on August 6. Its subsidiary received NMPA approval for trastuzumab rezetecan injection for its third indication, targeting HER2-positive colorectal cancer patients who failed prior oxaliplatin, fluorouracil, and irinotecan treatment — making it the first anti-HER2 product approved for colorectal cancer in China. Meanwhile, the company's JAK1 inhibitor aimaxitinib tablets secured a fifth indication for active radiographic-negative axial spondyloarthritis, achieving full-spectrum oral targeted management coverage for axial spondyloarthritis.Additionally, institutional interest has strengthened. Citigroup's long position in HENGRUI PHARMA H shares rose from 4.46% to 5.06% as of July 31, while Capital Group has been steadily accumulating shares. The board is scheduled to review interim results and consider a dividend on August 19.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185344761","isCrawlerRequest":true}